Haemonetics Expands Portfolio through Acquisition of Vivasure Medical Limited
Haemonetics Corporation, a global leader in medical technology, has recently made headlines with its strategic acquisition of Vivasure Medical Limited. This move marks a significant step forward in Haemonetics' mission to enhance patient outcomes with innovative medical solutions. Founded in Galway, Ireland, Vivasure Medical is recognized for its groundbreaking work in technologies aimed at percutaneous vessel closure, which has become an essential focus in interventional cardiology and vascular surgery.
The center of attention in this acquisition is Vivasure's pioneering PerQseal® Elite system. This innovative arterial closure device is designed to efficiently seal large-bore arteriotomies and venotomies, utilizing a proprietary bioabsorbable patch that offers a sutureless and fully absorbable solution. As medical procedures become increasingly advanced and minimally invasive, such innovations are crucial. The PerQseal Elite technology allows for seamless closure from within the vessel, significantly streamlining operations in structural heart and endovascular procedures.
In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for its PerQseal Elite system, and the product has received CE Mark approval in Europe. The release of results from the prospective ELITE arterial study showcased its promising efficacy, highlighting an impressive 0% major complication rate reported during thirty-day follow-ups, along with an accelerated hemostasis timeframe. These outstanding clinical outcomes underline Haemonetics' commitment to integrating advanced technology into their suite of medical solutions.
The acquisition further entails an upfront cash payment of €100 million, with an additional €85 million contingent on the sales growth of the acquired technology and other specific milestones. This strategic financial arrangement demonstrates Haemonetics' confidence in Vivasure's innovative offerings and their potential impact on the market. Financing for the transaction was facilitated through Haemonetics' available cash reserves, delineating a robust investment in the future of medical technology.
Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, expressed optimism regarding the acquisition, noting that it significantly enhances their closure device portfolio. He stated that the incorporation of Vivasure’s clinically differentiated technology positions Haemonetics as a leader in the large-bore closure market, providing substantial value to physicians and enhancing patient care standards. Crowley emphasized the potential of PerQseal Elite and its strong clinical performance data in securing Haemonetics' foothold in the rapidly-growing fields of structural heart and endovascular procedures.
On the other hand, Andrew Glass, CEO of Vivasure Medical Limited, reflected on the major strides made in advancing closure technology within the sector. He noted the firm's pride in what they have accomplished and acknowledged the support received from various stakeholders including clinicians, governmental bodies, and investors. Glass articulated the transformation Vivasure will undergo within the Haemonetics framework, emphasizing the potential for global scalability and enhanced resource availability for the PerQseal Elite system. This integration aims to streamline access to the groundbreaking technology, bringing its benefits to a broader audience of medical professionals and patients alike.
The acquisition stands to not only improve Haemonetics' portfolio but also heightens their competitive edge within the medical technology landscape. As healthcare institutions worldwide seek to adopt cutting-edge solutions to improve operational efficiency and patient outcomes, Haemonetics is setting the stage for significant advancements in vascular healthcare.
As Vivasure’s innovative solutions join Haemonetics' existing technologies, the partnership is poised to redefine standards in medical technology. With a shared commitment to prioritize patient welfare, the collaborative efforts are expected to yield transformative change across interventional procedures globally. The focus firmly lies on optimizing clinical outcomes while delivering value to healthcare providers, ultimately enhancing the overall quality of care across the industry.
The center of attention in this acquisition is Vivasure's pioneering PerQseal® Elite system. This innovative arterial closure device is designed to efficiently seal large-bore arteriotomies and venotomies, utilizing a proprietary bioabsorbable patch that offers a sutureless and fully absorbable solution. As medical procedures become increasingly advanced and minimally invasive, such innovations are crucial. The PerQseal Elite technology allows for seamless closure from within the vessel, significantly streamlining operations in structural heart and endovascular procedures.
In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for its PerQseal Elite system, and the product has received CE Mark approval in Europe. The release of results from the prospective ELITE arterial study showcased its promising efficacy, highlighting an impressive 0% major complication rate reported during thirty-day follow-ups, along with an accelerated hemostasis timeframe. These outstanding clinical outcomes underline Haemonetics' commitment to integrating advanced technology into their suite of medical solutions.
The acquisition further entails an upfront cash payment of €100 million, with an additional €85 million contingent on the sales growth of the acquired technology and other specific milestones. This strategic financial arrangement demonstrates Haemonetics' confidence in Vivasure's innovative offerings and their potential impact on the market. Financing for the transaction was facilitated through Haemonetics' available cash reserves, delineating a robust investment in the future of medical technology.
Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, expressed optimism regarding the acquisition, noting that it significantly enhances their closure device portfolio. He stated that the incorporation of Vivasure’s clinically differentiated technology positions Haemonetics as a leader in the large-bore closure market, providing substantial value to physicians and enhancing patient care standards. Crowley emphasized the potential of PerQseal Elite and its strong clinical performance data in securing Haemonetics' foothold in the rapidly-growing fields of structural heart and endovascular procedures.
On the other hand, Andrew Glass, CEO of Vivasure Medical Limited, reflected on the major strides made in advancing closure technology within the sector. He noted the firm's pride in what they have accomplished and acknowledged the support received from various stakeholders including clinicians, governmental bodies, and investors. Glass articulated the transformation Vivasure will undergo within the Haemonetics framework, emphasizing the potential for global scalability and enhanced resource availability for the PerQseal Elite system. This integration aims to streamline access to the groundbreaking technology, bringing its benefits to a broader audience of medical professionals and patients alike.
The acquisition stands to not only improve Haemonetics' portfolio but also heightens their competitive edge within the medical technology landscape. As healthcare institutions worldwide seek to adopt cutting-edge solutions to improve operational efficiency and patient outcomes, Haemonetics is setting the stage for significant advancements in vascular healthcare.
As Vivasure’s innovative solutions join Haemonetics' existing technologies, the partnership is poised to redefine standards in medical technology. With a shared commitment to prioritize patient welfare, the collaborative efforts are expected to yield transformative change across interventional procedures globally. The focus firmly lies on optimizing clinical outcomes while delivering value to healthcare providers, ultimately enhancing the overall quality of care across the industry.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.